U.S. Capital Wealth Advisors LLC Acquires 5,531 Shares of SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH)

U.S. Capital Wealth Advisors LLC lifted its holdings in SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) by 44.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,066 shares of the company’s stock after purchasing an additional 5,531 shares during the period. U.S. Capital Wealth Advisors LLC’s holdings in SPDR S&P Pharmaceuticals ETF were worth $719,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets increased its stake in SPDR S&P Pharmaceuticals ETF by 1.0% during the first quarter. BNP Paribas Financial Markets now owns 57,228 shares of the company’s stock valued at $2,468,000 after acquiring an additional 570 shares during the period. Principal Securities Inc. bought a new position in SPDR S&P Pharmaceuticals ETF during the fourth quarter valued at about $25,000. Wharton Business Group LLC increased its stake in SPDR S&P Pharmaceuticals ETF by 1.8% during the fourth quarter. Wharton Business Group LLC now owns 43,845 shares of the company’s stock valued at $1,825,000 after acquiring an additional 770 shares during the period. Simplex Trading LLC bought a new position in SPDR S&P Pharmaceuticals ETF during the fourth quarter valued at about $37,000. Finally, Advantage Trust Co bought a new position in SPDR S&P Pharmaceuticals ETF during the fourth quarter valued at about $174,000.

SPDR S&P Pharmaceuticals ETF Stock Performance

NYSEARCA XPH traded down $0.36 during trading on Friday, reaching $41.98. 57,358 shares of the company traded hands, compared to its average volume of 41,611. The stock’s 50 day moving average price is $40.99 and its two-hundred day moving average price is $41.71. The company has a market cap of $203.60 million, a price-to-earnings ratio of 14.39 and a beta of 0.87. SPDR S&P Pharmaceuticals ETF has a 1-year low of $34.67 and a 1-year high of $45.62.

About SPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.